Drug General Information
Drug ID	D0C8PE
Former ID	DNCL003124
Drug Name	JNJ-37822681
Drug Type	Small molecular drug
Indication	Schizophrenia [ICD9: 295; ICD10:F20]		Phase 2	[522393]
Company	Johnson & Johnson Pharmaceutical Research & Development
Structure		Download 2D MOL 3D MOL
Formula	C17H17F5N4
PubChem Compound ID	16058752
Target and Pathway
Target(s)	D(2) dopamine receptor	Target Info	Agonist	[532392]
KEGG Pathway	Rap1 signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Dopaminergic synapse
	Parkinson's disease
	Cocaine addiction
	Alcoholism
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Dopamine receptor mediated signaling pathway
	Nicotine pharmacodynamics pathway
Reactome	Dopamine receptors
	G alpha (i) signalling events
WikiPathways	Hypothetical Network for Drug Addiction
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Genes and (Common) Pathways Underlying Drug Addiction
	GPCR ligand binding
	GPCR downstream signaling
	Nicotine Activity on Dopaminergic Neurons
References
Ref 522393	ClinicalTrials.gov (NCT00728195) An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia. U.S. National Institutes of Health.
Ref 532392	Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D??receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D??receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.